Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer.
Clin Chem Lab Med
; 51(7): 1483-92, 2013 Jul.
Article
en En
| MEDLINE
| ID: mdl-23420288
ABSTRACT
BACKGROUND:
Serum HER2 (S-HER2) was approved in 2003 by the US Food and Drug Administration (FDA) for monitoring trastuzumab treatment in tissue HER2 positive breast cancer patients. Information of the value of S-HER2 is scarce. We hypothesised that S-HER2 would reflect the clinical effect of trastuzumab.METHODS:
We followed 48 patients eligible for trastuzumab treatment for up to 6 years or until death. S-HER2 was measured on an ADVIA Centaur System and S-Trastuzumab was measured by an in-house developed fluorescent enzyme immunoassay system on the ImmunoCap 100.RESULTS:
A decrease in S-HER2 of ≥ 20% was correlated to no progression in the disease in 20 out of 21 clinical courses (p<0.0001). An increase in S-HER2 of ≥ 20% was correlated to progression in the disease in 40 out of 44 clinical courses (p<0.0001). Patients with no recurrence after trastuzumab treatment (n=18) had a median S-HER2 concentration of 10.5 µg/L, whereas patients alive with recurrence (n=13) had a median S-HER2 of 20.1 µg/L (p=0.002). Patients who died prompted by recurrence (n=17) had a median S-HER2 of 232.4 µg/L at latest measurement before death (p=<0.0001) compared to patients without recurrence. In two patients with S-HER2 values above 1000 µg/L the concentrations of S-trastuzumab were measured below the target trough concentration in serum of 10 mg/L.CONCLUSIONS:
Decreasing values of S-HER2 predicts response to treatment whereas increasing levels predict resistance. S-HER2 above 1000 µg/L warns that standard doses of trastuzumab may be insufficient as reflected by low concentrations of S-trastuzumab.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Carcinoma in Situ
/
Biomarcadores de Tumor
/
Carcinoma Ductal de Mama
/
Receptor ErbB-2
/
Biomarcadores Farmacológicos
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Clin Chem Lab Med
Asunto de la revista:
QUIMICA CLINICA
/
TECNICAS E PROCEDIMENTOS DE LABORATORIO
Año:
2013
Tipo del documento:
Article
País de afiliación:
Dinamarca